2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 542

‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 492

‘It Felt Like I Was Walking on Rocks” Patients Share First Symptoms of RA

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 134

‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 583

A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 511

A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 524

A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 219

A Fibromyalgia Assessment Screening Tool on a Multidimensional Health Assessment Questionnaire (MDHAQ) Which Does Not Include a Self-Report RADAI Painful Joint Count (RADAI), FAST3nJC, Recognizes Fibromyalgia Similarly to Other FAST3 Indices Which Include a RADAI

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 224

A Functional Exercise Program Improves Pain and Health Related Quality of Life in Patients with Fibromyalgia: A Randomized Controllel Trial

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 192

A Healthy Plant-Rich Diet and the Risk of Rheumatoid Arthritis in Women

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 646

A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 54

A Metagenome-wide Association Study of Gut Microbiome Revealed Novel Etiology of Rheumatoid Arthritis in the Japanese Population

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 755

A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 641

A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 424

A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 6

A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts

Cytokines & Cell Trafficking Poster

1
2
3
…
65
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].